Is Retatrutide FDA approved?

Retatrutide is investigational and not FDA approved. It is discussed for research and educational purposes only, not as medical guidance.

How is 5-Amino-1MQ administered in research settings?

In research settings, 5-Amino-1MQ is typically administered via the oral route. PeptideBase does not provide dosing or administration instructions.

How is Retatrutide administered in research settings?

In research settings, Retatrutide is typically administered via the subcutaneous route. PeptideBase does not provide dosing or administration instructions.

Home›Research›Compare›5-Amino-1MQ vs Retatrutide

Peptide Comparison

5-Amino-1MQ vs Retatrutide

Name: 5-Amino-1MQ vs Retatrutide — Per-mg Price Comparison
Creator: PeptideBase
License: https://peptidebase.io/terms

Both are Metabolic peptides.

5-Amino-1MQ

5-Amino-1-methylquinolinium

Fat LossResearch Only

49 providers listed

Full 5-Amino-1MQ profile →

Retatrutide

LY3437943

Fat LossInvestigationalResearch Only

Half-life: ~6 days

98 providers listed

Full Retatrutide profile →

Bottom line

Retatrutide carries stronger published evidence (RCT, 13 key studies) than 5-Amino-1MQ (Animal, 1); both are research compounds.

Quick Verdict

5-Amino-1MQ

Evidence

Preclinical

Half-life

—

Retatrutide

Evidence

Clinical

Half-life

~6 days

Which One Should You Choose?

Your goal	Better option
Stronger clinical evidence	Retatrutide
Further along in FDA review	Retatrutide
Oral administration option	5-Amino-1MQ
Lower typical price per mg	5-Amino-1MQ
More provider options (49 vs 98)	Retatrutide

Research summary only — not medical advice. Consult a qualified provider before making any decisions.

Side-by-Side Comparison

5-Amino-1MQ

Retatrutide

Mechanism Family

Metabolic

Half-life

—

~6 days

FDA Status

unknown

investigational

Admin Routes

oral

subcutaneous

Availability

Research Only

Providers

49 listed

98 listed

Avail. Notes

—

Triple GIP/GLP-1/glucagon agonist by Eli Lilly. Pivotal Phase 3 readouts across obesity (TRIUMPH-1, May 2026), obesity + knee osteoarthritis (TRIUMPH-4, Dec 2025), and type 2 diabetes (TRANSCEND-T2D-1, Mar 2026); OSA trial in program. Not FDA-approved; regulatory submission expected 2026–2027. NCT05929066.

Research Evidence

5-Amino-1MQ

PreclinicalAnimal · 1 key study · most recent 2022

Retatrutide

ClinicalRCT · 13 key studies · most recent 2026

Research Citations

5-Amino-1MQ

Animal2022 · Scientific Reports

NNMT inhibitor in diet-induced obese mice: effects on body weight, body fat, and energy expenditure

Retatrutide

RCT2023 · New England Journal of Medicine

Triple-hormone-receptor agonist retatrutide for obesity — a phase 2 trial

Review2026 · Eur J Clin Pharmacol

Dysesthesia associated with GLP-1 agonist therapies: data-mining analysis and literature review.

Review2026 · Lancet Diabetes Endocrinol

Beyond weight loss: multisystem benefits of obesity medications.

Cohort2026 · BMJ

Retatrutide: Triple acting jab for type 2 diabetes lowers blood sugar and boosts weight loss, trial reports.

+9 more

About 5-Amino-1MQ

Inhibits NNMT enzyme, increasing SAM (S-adenosylmethionine) availability. Alters adipocyte gene expression to reduce fat cell size and may increase brown adipose tissue activity via epigenetic mechanisms.

Research Areas

fat cell reductionmetabolic rateadipose tissue modulation

About Retatrutide

Triple GIP/GLP-1/glucagon receptor agonist; targets three pathways for synergistic fat reduction

Research Areas

profound weight lossappetite suppressionmetabolic improvement

Safety Profile

Information below reflects published research data only — not medical advice. Consult a qualified provider before use.

5-Amino-1MQ

No established clinical contraindications. This is an investigational compound with limited human data and has not been evaluated by the FDA for safety in this context. Consult a qualified clinician.

Retatrutide

Absolute Contraindications

Personal or family history of medullary thyroid carcinoma (MTC)Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)Known hypersensitivity to the drug or excipients

Warnings & Cautions

Acute pancreatitisPregnancy (discontinue; not for use in pregnancy)Gallbladder disease / cholelithiasisDiabetic retinopathy complications (reported with GLP-1 receptor agonist use)Severe GI disease / gastroparesis / ileus riskHypoglycemia when combined with insulin or sulfonylureasAcute kidney injury secondary to volume depletion

Class-based (investigational)

Price (per mg)

5-Amino-1MQ

$5.00/mg

$2.88 – $8.00 range

20 vendors

View price index →Find providers →

Retatrutide

$10.90/mg

$8.34 – $12.73 range

7 vendors

View price index →Find providers →

Find Providers

Where to source these peptides

Providers offering

5-Amino-1MQ

49 listed

Browse directory →

Providers offering

Retatrutide

98 listed

Browse directory →

PeptideBase lists providers for educational research purposes only. Always consult a qualified healthcare professional before obtaining or using any peptide.

More Metabolic Comparisons

Browse all peptides →

Educational research tools — not medical advice.

Cite this page

Data last updated July 27, 2026

Free to reference and republish with attribution to PeptideBase. Choose a format:

PeptideBase. (2026). 5-Amino-1MQ vs Retatrutide — Per-mg Price Comparison. Retrieved July 29, 2026, from https://peptidebase.io/peptides/compare/5-amino-1mq/retatrutide

https://peptidebase.io/peptides/compare/5-amino-1mq/retatrutide Methodology License Download JSON Download CSV